Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 1/20 | 1.00 |
| ▸ | PARP1 | P09874 | 18/20 | 0.82 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496129 | 1.00 | PIM1 (1.00) | PIM1CSNK1DPARP1ROCK1 | |
| SCHEMBL61589 | 0.92 | PIM1 (0.85) | PIM1CSNK1DPARP1 | |
| SCHEMBL51663 | 0.92 | PIM1 (0.85) | PIM1CSNK1DPARP1 | |
| SCHEMBL1319786 | 0.91 | PIM1 (0.84) | PIM1CSNK1DPARP1 | |
| SCHEMBL14336521 | 0.91 | PARP1 (0.83) | PIM1CSNK1DPARP1ROCK1 | |
| SCHEMBL61587 | 0.91 | PARP1 (0.83) | PIM1CSNK1DPARP1 | |
| SCHEMBL10035767 | 0.91 | PIM1 (0.82) | PIM1CSNK1DPARP1 | |
| SCHEMBL51776 | 0.90 | PIM1 (0.82) | PIM1CSNK1DPARP1 | |
| SCHEMBL61766 | 0.90 | PARP1 (0.82) | PIM1CSNK1DPARP1 | |
| SCHEMBL22674578 | 0.90 | PARP1 (0.82) | PIM1CSNK1DPARP1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360538-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-11-19 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20190046665-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190046665-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-14 | — | — | US | disclosed |
| WO-2015100257-A1 | METHODS AND ASSAYS FOR DETERMINING REDUCED BRCA1 PATHWAY FUNCTION IN A CANCER CELL | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-02 | — | — | WO | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| EP-2061765-B1 | Serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES INC (TW) | 2014-10-22 | — | — | EP | disclosed |
| US-20130116284-A1 | LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116284-A1 | LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008016707-A2 | USE OF IL-6 IN THE DIAGNOSIS AND TREATMENT OF NEUROINFLAMMATORY CONDITIONS | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-02-07 | — | — | WO | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1633362-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004105700-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | GUILDFORD PHARMACEUTICALS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004105700-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | GUILDFORD PHARMACEUTICALS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | PIM1 1226/4885CSNK1D 2063/4885PARP1 1/4885 |
| US-20190046665-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | PARP2, PARP1, PARP3 | PIM1 1871/4885CSNK1D 2049/4885PARP1 2/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | PIM1 3448/4885CSNK1D 787/4885PARP1 1298/4885 |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | PARP1, PARP2, PARP3 | PIM1 1069/4885CSNK1D 2130/4885PARP1 1/4885 |
| US-20200360538-A1 | METHODS OF CANCER DETECTION USING PARPI-FL | PARP2, PARP1, PARP3 | PIM1 1871/4885CSNK1D 2049/4885PARP1 2/4885 |
| US-20130116284-A1 | LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF | PARP1, PARP2, PARP6 | PIM1 2769/4885CSNK1D 4041/4885PARP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.